Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 3/20 | 0.68 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.68 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.68 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.68 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.68 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.68 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.68 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.68 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.68 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.68 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.68 |
| ▸ | ARG1 | P05089 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9808337 | 1.00 | THRB (0.68) | THRBGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL9808268 | 1.00 | THRB (0.68) | THRBGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL9603867 | 0.92 | MEN1 (0.73) | THRBGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL9808299 | 0.92 | MEN1 (0.73) | THRBGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL9808303 | 0.92 | MEN1 (0.73) | THRBGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL9850288 | 0.81 | MEN1 (0.58) | THRBGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL9808316 | 0.81 | THRB (0.45) | THRBGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL9808322 | 0.81 | THRB (0.45) | THRBGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL9808318 | 0.81 | THRB (0.45) | THRBGRIN2DGRIN3BGRIN1GRIN2A | |
| Selfotel SCHEMBL20553546 | 0.81 | MEN1 (1.00) | THRBGRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 280 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250351686-A1 | DISPLAY DEVICE | SAMSUNG DISPLAY CO LTD (KR) | 2025-11-13 | — | — | US | claimed |
| WO-2025103290-A1 | MRNA VACCINE AGAINST HERPES ZOSTER AND PREPARATION METHOD THEREFOR | 石药集团巨石生物制药有限公司 | 2025-05-22 | — | — | WO | claimed |
| EP-4506353-A1 | MRNA CAP ANALOG AND USES THEREOF | Hanmi Fine Chemical Co., Ltd. (KR) | 2025-02-12 | — | — | EP | claimed |
| WO-2024260359-A1 | MRNA VACCINE AGAINST RESPIRATORY SYNCYTIAL VIRUSES AND PREPARATION METHOD THEREFOR | 石药集团巨石生物制药有限公司 | 2024-12-26 | — | — | WO | claimed |
| CN-118974071-A | MRNA cap analogues and uses thereof | 韩美精密化学株式会社 | 2024-11-15 | — | — | CN | claimed |
| EP-4397668-A1 | MRNA CAP ANALOGUE AND USE THEREOF | Hanmi Fine Chemical Co., Ltd. (KR) | 2024-07-10 | — | — | EP | claimed |
| CN-117940441-A | MRNA cap analogues and uses thereof | 韩美精密化学株式会社 | 2024-04-26 | — | — | CN | claimed |
| CN-115466398-B | Preparation method and application of organic quinone polymer positive electrode material PPPA for water-based zinc ion battery | 东南大学 | 2023-11-24 | — | — | CN | claimed |
| WO-2023191342-A1 | MRNA CAP ANALOG AND USES THEREOF | 한미정밀화학 주식회사 | 2023-10-05 | — | — | WO | claimed |
| WO-2023098273-A1 | TARGET FOR SCREENING DRUG FOR INHIBITING INTESTINAL FATTY ACID INTAKE AND PREVENTING FATTY LIVER, AND USE THEREOF | 南京医科大学 | 2023-06-08 | — | — | WO | claimed |
| CN-114164249-B | Drug target for screening and inhibiting intestinal fatty acid uptake and preventing and treating fatty liver and application thereof | 南京医科大学 | 2022-11-15 | — | — | CN | claimed |
| CN-114164249-A | Drug target for screening and inhibiting intestinal fatty acid uptake and preventing and treating fatty liver and application thereof | 南京医科大学 | 2022-03-11 | — | — | CN | claimed |
| US-20150119327-A1 | DRUG SCREENING PLATFORM FOR RETT SYNDROME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-04-30 | — | — | US | claimed |
| EP-2841067-A2 | A DRUG SCREENING PLATFORM FOR RETT SYNDROME | The Regents of The University of California (US) | 2015-03-04 | — | — | EP | claimed |
| WO-2013163455-A2 | A DRUG SCREENING PLATFORM FOR RETT SYNDROME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-10-31 | — | — | WO | claimed |
| US-5614509-A | Pharmaceutical agents for preventing the development of tolerance during the treatment with benzodiazepine-receptor-binding active ingredients | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-03-25 | — | — | US | claimed |
| EP-0488959-A2 | New uses of competitive NMDA receptor antagonists | SANDOZ LTD. (CH) | 1992-06-03 | — | — | EP | claimed |
| EP-0203891-B1 | CERTAIN PHOSPHONIC ACIDS AND DERIVATIVES | CIBA-GEIGY AG (CH) | 1991-05-15 | — | — | EP | claimed |
| US-4898854-A | NERVOUS SYSTEM DISORDERS | CIBA-GEIGY CORPORATION (US) | 1990-02-06 | — | — | US | claimed |
| EP-0203891-A2 | Certain phosphonic acids and derivatives | CIBA-GEIGY AG (CH) | 1986-12-03 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119327-A1 | DRUG SCREENING PLATFORM FOR RETT SYNDROME | GRIN2A, GRIN1, GRIN2B | THRB 780/4885GRIN2D 11/4885GRIN3B 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.